SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary Kennedy's 'misinformation and lies.' ...

Messenger Ribonucleic Acid (mRNA) vaccines gained global recognition during the Coronavirus Disease 2019 (COVID-19) pandemic, proving their value through rapid development, high efficacy ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer. (Photo by Aaron Chown/PA Images via Getty Images ...

In March, short sellers collectively increased their negative bets on the broader healthcare industry. Read more details here ...

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...